Kidney disease decisions — 2025

The Board remanded the veteran's claims for service connection of right shoulder disability, renal disease, prostate disability, and neurological tremors due to inadequate VA examinations.

The Board granted service connection for ischemic heart disease, chronic kidney disease, diabetes mellitus type II, hypertension, arteriosclerosis, and erectile dysfunction.

The Board remands the claims for service connection for obstructive sleep apnea and chronic kidney disease due to inadequate medical opinions provided by the VA.

The Board denied service connection for the veteran's chronic kidney disease, finding no evidence that it was related to his military service or aggravated by it.

The Board remanded the claims for service connection for bladder cancer, lung cancer, and kidney cancer. The Veteran's exposure to Agent Orange in Okinawa is being reviewed.

The Veteran's death from gastric cancer and renal failure was service-connected due to exposure to contaminated water at Camp Lejeune.

The Board denied service connection for all claimed conditions except bilateral hearing loss, which was remanded. The Veteran's surviving spouse is the appellant.

Service connection for hypothyroidism is granted. Other conditions are remanded for further evaluation.

The Board remanded the appeals for service connection of kidney stones, vertigo, bilateral foot fungus, and urinary tract infection. The Veteran's VA treatment records need to be obtained, and further medical opinions are required.

The Board remanded the Veteran's claims for service connection for chronic kidney failure and obstructive sleep apnea due to inadequate VA examinations.

The veteran's service connection for diabetes, ischemic heart disease, chronic kidney disease, and peripheral neuropathies was granted effective August 10, 2022.

The appeal for service connection of chronic kidney disease due to contaminated water at Camp Lejeune is remanded. The Board will reconsider the November 3, 2021 VA medical opinion and obtain a TERA memorandum.

The veteran's claim for service connection for a renal disability was denied. The veteran's claim for service connection for peripheral neuropathy from September 16, 2016, to November 1, 2016, was granted.

The Board remanded the Veteran's claims for service connection for kidney disability and thyroid cancer, as well as a higher rating for PTSD. The RO did not comply with previous directives and the medical opinions obtained were inadequate.

The veteran's appeal was dismissed because the veteran requested to withdraw it.

The veteran's claim for a higher rating for sarcoidosis was denied. The veteran was granted a 10 percent rating for hypertension and an earlier effective date of May 15, 2018, for service connection. The veteran's claim for a higher rating for chronic kidney disease was denied, but an earlier effective date of May 15, 2018, for service connection was granted. The veteran's claim for a compensable rating for erectile dysfunction (ED) was denied, but an earlier effective date of May 15, 2018, for service connection was granted. Several issues were remanded.

The Board granted service connection for the cause of the Veteran's death, finding that his service-connected bilateral foot and lower extremity disabilities contributed to his death by causing a fall that resulted in a femur fracture.

The Board denied service connection for asthma, end stage renal disease, myocardial infarction, hypertension, and vascular disease. The evidence did not show these conditions were incurred in service or within one year of separation.

The Board denied service connection for hypertension, a heart condition, multiple myeloma, anemia, tinnitus, and a kidney condition. The Veteran's claims were based on alleged exposure to Agent Orange during his service in Okinawa.

The veteran's PTSD with persistent depressive disorder is service-connected at 70% from March 6, 2020. The veteran's hypertension rating increased to 10% from April 9, 2017. Increased ratings for atrial fibrillation, kidney cancer residuals, and squamous cell carcinoma were denied.